Patent ID: 8431686

Claim:
A monoclonal antibody, or fragment thereof, capable of binding to the LG4/5 domain of chain alpha3 of human protein laminin-5 (SEQ ID NO:3), and inhibiting the binding of syndecan-1 to said laminin-5 alpha3 chain LG4/5 domain, wherein: A) said monoclonal antibody, or fragment thereof, binds to the epitope of sequence: LDSKPLYTPSSSF (SEQ ID NO: 25); or B) 1) said monoclonal antibody comprises: a) a light chain comprising three light chain complementary regions (CDRs) having the following amino acid sequences: i) the light chain CDR1: QSLLDSTGRTY (SEQ ID NO:4): ii) the light chain CDR2: LVS; iii) the light chain CDR3: WQGTHFPHT (SEQ ID NO:5); and a light chain framework sequence from an immunoglobulin light chain; and b) a heavy chain comprising three heavy chain complementary regions (CDRs) having the following amino acid sequences: i) the heavy chain CDR1: GYTFTEYT (SEQ ID NO:6); ii) the heavy chain CDR2: INPKNGDT (SEQ ID NO:7); iii) the heavy chain CDR3: ASPDLPPMDY (SEQ ID NO:8); and a heavy chain framework sequence from an immunoglobulin heavy chain; or 2) said monoclonal antibody comprises : a) a light chain comprising three light chain complementary regions (CDRs) having the following amino acid sequences: i) the light chain CDR1: ESVEYYGTSL (SEQ ID NO:32): ii) the light chain CDR2: TAS (SEQ ID NO: 33); iii) the light chain CDR3: QQSRKVPYT (SEQ ID N 0 :34); and a light chain framework sequence from an immunoglobulin light chain; and b) a heavy chain comprising three heavy chain complementary regions (CDRs) having the following amino acid sequences: i) the heavy chain CDR1: GFTFSDYY (SEQ ID NO:29); ii) the heavy chain CDR2: ITNIGGNT (SEQ ID NO:30); iii) the heavy chain CDR3: ARPPSYGNYGYFNV (SEQ ID NO:31); and a heavy chain framework sequence from an immunoglobulin heavy chain.; or 3) said monoclonal antibody comprises: : a) a light chain comprising three light chain complementary regions (CDRs) having the following amino acid sequences: i) the light chain CDR1: SSIAH (SEQ ID NO:38); ii) the light chain CDR2: STS (SEQ ID NO:39); iii) the light chain CDR3: HQRSSYPFT (SEQ ID NO:40); and a light chain framework sequence from an immunoglobulin light chain; and b) a heavy chain comprising three heavy chain complementary regions (CDRs) having the following amino acid sequences: i) the heavy chain CDR1: GYSLATYW (SEQ ID NO:35); ii) the heavy chain CDR2: IYPGNGET (SEQ ID NO:36); iii) the heavy chain CDR3: TRERADVYYYGMDY (SEQ ID NO:37); and a heavy chain framework sequence from an immunoglobulin heavy chain.